Skip to content
Does the October share price for Merck & Co., Inc. (NYSE:MRK) reflect what it's really worth? Today, we will estimate......
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop......
KeyBanc Capital Markets data indicates a month-on-month decline in AT&T Inc's (NYSE: T) wireless postpaid average revenue per user, suggesting limited improvement in service revenue in the third quarter. The AT&T Analyst: Brandon Nispel downgraded AT&T from Sector Weight to Underweight with a $25 price target. The AT&T Thesis: The company is "secularly and competitively challenged," while expectations seem high across most segments, Nispel said in a downgrade note.The analyst named the following takeaways from KeyBanc's proprietary Key First Look Data: * Declining postpaid ARPUs on both a month-on-month and year-on-year basis. * A deceleration in DirecTV indexed customers from negative 16% year-on-year in July to negative 18% in August. * Rapid deceleration in DirecTV ARPUs to 0.5% year-on-year in August, from 3.8% in July and "mid to high single-digit growth previously." * Net additions at AT&T TV and AT&T TV Now of around 200,000 and 100,000 in the third quarter....
Questions have surfaced about the lack of transparency surrounding Trump''s condition, and how serious his condition might be despite rosy assurances by his medical team....
Here's what Wall Street is saying about why the stock market is rallying as President Trump continues to battle COVID-19....
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]...
The focus and resources of several biotech and pharma companies have shifted toward developing a vaccine or treatment for COVID-19. However, there are many companies in the healthcare space that have a strong product portfolio and a promising pipeline and could offer attractive investment opportunities for investors irrespective of their success in coming up with a treatment for the novel coronavirus.We will analyze two leading pharma companies Gilead Sciences and Pfizer and use Tipranks' Stock Comparison tool to arrive at the stock which offers a more compelling investment opportunity.Pfizer (PFE)Pfizer has been in the news for its COVID-19 vaccine candidate BNT162b2, which the company is developing in collaboration with BioNTech (BNTX). Last month, Pfizer and BioNTech proposed expanding the late-stage trial of BNT162b2 to include 44,000 participants, up from the originally planned 30,000 participants. The two companies reaffirmed that they expect a conclusive readout on the efficacy of the vaccine by...
